Trending
- Pyruvate carboxylase drives therapeutic resistance to KRAS G12C inhibitors in KEAP1-mutant lung cancer
- Supercentenarians’ superpower to suppress cancer
- Making Outpatient Cellular Therapy Dosing the Default in Multiple Myeloma
- Bruce Haffty, MD, and Mutlay Sayan, MD, on Radiation Oncology’s Next Frontier and Mentorship
- FDA OKs Pirtobrutinib in Frontline CLL/SLL
- Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
- First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival
- Preoperative SBRT Shows High Resection Rates in Pancreatic Adenocarcinoma
Saturday, October 3